Investigational Senolytic drug improves macular degeneration

Injected directly into the eye, but at least this adds to my hopes about future successes in the field in general.

An investigational drug targeting senescent cells achieved sustained improvement in visual acuity in patients with diabetic macular edema (DME) or neovascular age-related macular degeneration (AMD), a small pilot study showed.

After single doses of UBX1325, four of eight evaluable patients with advanced DME had at least 10 letters of improvement in best corrected visual acuity (BCVA) at 24 weeks, and five of eight had improvement of at least five letters. Nine evaluable patients with AMD had sustained improvement of three to four letters at 24 weeks.

2 Likes